Login to Your Account



EntreMed, Allergan Collaborate On Ophthalmic Uses Of Panzem

By Kim Coghill


Thursday, January 24, 2002
Allergan Inc. struck a five-year deal potentially worth more than $40 million with EntreMed Inc. to develop and commercialize the latter’s angiogenic inhibitor, Panzem, for ophthalmolic uses.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription